The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 18, 2015
Filed:
Mar. 30, 2012
Applicants:
David B. Masters, Minneapolis, MN (US);
Eric P. Berg, Plymouth, MN (US);
Inventors:
David B. Masters, Minneapolis, MN (US);
Eric P. Berg, Plymouth, MN (US);
Assignee:
Gel-Del Technologies, Inc., St. Paul, MN (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/726 (2006.01); A61K 31/727 (2006.01); A61K 31/728 (2006.01); A61K 31/715 (2006.01); A61K 8/64 (2006.01); A61K 8/65 (2006.01); A61K 31/70 (2006.01); A61K 35/545 (2015.01); A61K 38/39 (2006.01); A61K 45/06 (2006.01); A61L 27/20 (2006.01); A61L 27/22 (2006.01); A61L 27/34 (2006.01); A61L 27/48 (2006.01); A61L 27/50 (2006.01); A61L 31/10 (2006.01); A61L 33/12 (2006.01); A61Q 19/08 (2006.01); A61M 25/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/715 (2013.01); A61K 8/64 (2013.01); A61K 8/65 (2013.01); A61K 31/70 (2013.01); A61K 31/726 (2013.01); A61K 31/727 (2013.01); A61K 31/728 (2013.01); A61K 35/545 (2013.01); A61K 38/39 (2013.01); A61K 45/06 (2013.01); A61L 27/20 (2013.01); A61L 27/22 (2013.01); A61L 27/34 (2013.01); A61L 27/48 (2013.01); A61L 27/507 (2013.01); A61L 31/10 (2013.01); A61L 33/12 (2013.01); A61Q 19/08 (2013.01); A61K 38/00 (2013.01); A61K 2800/91 (2013.01); A61M 25/0045 (2013.01);
Abstract
Biomaterials and the related methods of making and using biomaterials for wound treatment. The biomaterial defines an amorphous material that is crosslinked with one or more crosslinking agents an includes aggregated complexes having homogenously distributed biocoacervated components. The biocoacervated components include one or more soluble or solubilized primary proteins combined with one or more glycosaminoglycans and one or more biocompatible solvents. The biomaterial can be utilized by administering the biomaterial to a wound.